Get the Stockscreener App
1.55
1.88%
-0.05
Pluri Inc stock is traded at $1.55, with a volume of 44,422.
It is down -1.88% in the last 24 hours and down -15.59% over the past month.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
See More
Previous Close:
$1.60
Open:
$1.63
24h Volume:
44,422
Relative Volume:
1.71
Market Cap:
$16.72M
Revenue:
$1.08M
Net Income/Loss:
$-26.95M
P/E Ratio:
-0.5398
EPS:
-2.8712
Net Cash Flow:
$-21.69M
1W Performance:
-14.67%
1M Performance:
-15.59%
6M Performance:
-57.68%
1Y Performance:
-68.44%
1-Day Range:
$1.55
$1.67
1-Week Range:
$1.55
$1.82
52-Week Range:
$1.45
$5.68
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
1.55 | 17.26M | 1.08M | -26.95M | -21.69M | -2.8712 |
VRTX
Vertex Pharmaceuticals Inc
|
515.31 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.34 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pluri Inc Stock (PLUR) Latest News
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment - GlobeNewswire
Pluri Inc (PLUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pluri Inc. Revenue Breakdown – NASDAQ:PLUR - TradingView
Pluri Inc (PLUR) Stock News Today - TradingKey
Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cellav Health and Aesthetics Ltd Completes Regulatory Registration of Regenativo+ in the UK - marketscreener.com
Pluri's subsidiary Cellav completes UK regulato... - Pluang
Pluri subsidiary completes UK regulatory registration for aesthetics product - Investing.com
Pluri’s Regenativo+ Is Registered for Sale in a $900M UK Market - Stock Titan
Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pluri Inc. (PLUR) Gains Slightly as Stock Tests Key Resistance Near $1.76Wave Equality - dars.gov.et
Pluri Inc (PLUR) Balance Sheet - TradingKey
PLUR|Pluri Inc|Price:1.550|Chg%:-0.010 - TradingKey
Pluri Inc (PLUR) Cash Flow - TradingKey
Pluri Inc (PLUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PLUR|Pluri Inc|Price:1.640| - TradingKey
Pluri Inc (PLUR) Earnings Date & Reports & Earnings News - TradingKey
Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pluri Inc (PLUR) Institutional Confidence - TradingKey
PLUR|Pluri Inc|Price:1.780|Chg%:-0.040 - TradingKey
Pluri Inc. Q2 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentsProfit Guidance Range - dars.gov.et
Pluri Inc (PLUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to revenue forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Enterprise value to revenue forward of Pluri Inc. – FWB:4DX - TradingView
Plurilock Security Inc.'S Aurora Subsidiary Announces Selection as SEWP VI Awardee Enabling U.S. Federal Agencies to Procure It and Cybersecurity Solutions - marketscreener.com
Pluri Inc. (PLUR) Q2 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Revision Trend - dars.gov.et
Pluri Inc. (PLUR) Rallies 3.33% from Support: Key Levels to WatchReversal Setup Alerts - dars.gov.et
Price to book forward of Pluri Inc. – LS:A408KW - TradingView
Pluri in ongoing talks to extend EIB financing - The Globe and Mail
Pluri Inc. Files 8-K: Company Updates, NASDAQ Listing, and EIB Loan Discussions – July 2026 - Minichart
Pluri chairman raises stake above 30%; shares up - MSN
Pluri's Chairman Increases Investment and Ownership Stake (PLUR) - GuruFocus
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30% - marketscreener.com
Pluri Chairman Builds 30%-Plus Position With $17M Investment - Stock Titan
Pluri Receives Nasdaq Non-Compliance Notice, Faces Delisting Risk - TipRanks
Pluri Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Pluri Inc. Q2 2026 Earnings: EPS Miss Reflects Ongoing R&D InvestmentOne-Time Gain Impact - dars.gov.et
Pluri Inc. (PLUR) Q2 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentNon-GAAP Earnings - dars.gov.et
Pluri (PLUR) director Doron Shorrer files Form 3 listing share holdings - Stock Titan
PLURPluri Inc Latest SEC Filings - Finviz
Pluri Inc. Q2 2026 Earnings: EPS Misses Estimates as Stock Holds SteadyDividend Increase Stocks - dars.gov.et
Pluri Inc. Q2 2026 Earnings: Wider-than-Expected Loss Drives Stock DeclineSlow Growth Warning - dars.gov.et
Pluri (NASDAQ: PLUR) director logs RSU grant as 625,000 warrants expire - Stock Titan
Synthetic Stem Cell Market to Witness Massive Growth by 2033 | - openPR.com
Form 13D/A Pluri Inc. For: 1 July By Investing.com - Investing.com UK
Price to sales forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Enterprise value to EBITDA forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Price to earnings forward of Pluri Inc. – NASDAQ:PLUR - TradingView
Price to earnings forward of Pluri Inc. – TASE:PLUR - TradingView
Pluri Inc. Actuals & Estimates (NASDAQ:PLUR) - TradingView
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):